Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observer-Blind, Randomized, Controlled Study of Immunogenicity and Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

NCT05525208 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05525208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05525208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observer-Blind, Randomized, Controlled Study of Immunogenicity and Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
Lead sponsor
PT Bio Farma
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2022
Completion date
August 4, 2023
Enrollment
696 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19